Marvin Edeas - LinkedIn

Marvin Edeas - Important Research on HIV

Back in the '90s, Marvin Edeas ( conducted significant studies on the AIDS virus. He figured out the role of co-infections and oxidative stress in HIV patients at Paris Descartes University. The factors that result in blastogenic plasma in Type 1 cases of HIV were revealed by him in 1997. When the first clinical study which looked into the impact of antiretroviral therapy on lactic acidosis and hyperlactatemia occurred, Marvin Edeas participated.

Marvin Edeas - Background

At Paris-Descartes University, Marvin Edeas pursued a curriculum on infectious diseases. In 1998, he gained his doctorate on HIV infections in symptomless patients from Antoine Béclère Hospital. From 2004 to the year 2013, he was a teacher at the Paris 13 Bobigny and Poitiers Universities. Marvin Edeas was employed by the Department of Pulmonary Diseases at Armand Trousseau Hospital in the early part of the 1990's.

Oysters and Peptides Derived from Hydrolysates Modulate Oxidative Stress

The patents of Marvin Edeas had to do with the use of an oyster enzyme hydrolyzate within a composition that modulates oxidative stress and eliminates free radicals. He has filed patents, in Europe and in the United States. Two Nrf-2 modulators isolated from peptides and proteins, which can trigger the antioxidant system of defence, were identified by Marvin Edeas. Cosmetology, dietetics and medicine could all gain advantages from Oyster hydrolyzate.

Marvin Edeas is founder and Chair of the ISANH (International Society of Antioxidants in Nutrition & Health) which was established in 1998. He, ISANH and the SFA strive to transfer their research to real applications whether clinical, pharmaceutical, nutritional or cosmetic. The well-known French Society of Antioxidants is a society which Marvin Edeas chairs.